Barclays PLC increased its holdings in shares of Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) by 342.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,439 shares of the company's stock after acquiring an additional 41,358 shares during the quarter. Barclays PLC owned approximately 0.14% of Viemed Healthcare worth $392,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in Viemed Healthcare by 11.4% in the second quarter. Bank of New York Mellon Corp now owns 95,388 shares of the company's stock worth $625,000 after buying an additional 9,792 shares during the period. Rhumbline Advisers lifted its position in Viemed Healthcare by 9.4% in the 2nd quarter. Rhumbline Advisers now owns 42,011 shares of the company's stock valued at $275,000 after purchasing an additional 3,613 shares during the last quarter. Victory Capital Management Inc. lifted its position in Viemed Healthcare by 21.1% in the 2nd quarter. Victory Capital Management Inc. now owns 12,791 shares of the company's stock valued at $84,000 after purchasing an additional 2,226 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Viemed Healthcare by 50.9% during the 2nd quarter. Renaissance Technologies LLC now owns 438,700 shares of the company's stock valued at $2,873,000 after purchasing an additional 147,900 shares during the period. Finally, Apis Capital Advisors LLC increased its stake in shares of Viemed Healthcare by 193.0% in the second quarter. Apis Capital Advisors LLC now owns 234,400 shares of the company's stock valued at $1,535,000 after purchasing an additional 154,400 shares during the period. Institutional investors own 74.24% of the company's stock.
Viemed Healthcare Stock Performance
Shares of VMD traded down $0.02 during mid-day trading on Friday, reaching $8.15. 150,583 shares of the company's stock traded hands, compared to its average volume of 126,969. Viemed Healthcare, Inc. has a 12 month low of $6.21 and a 12 month high of $10.44. The stock has a market capitalization of $317.36 million, a P/E ratio of 30.19 and a beta of 1.47. The business's 50-day moving average price is $8.44 and its 200-day moving average price is $7.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.19 and a current ratio of 1.31.
Viemed Healthcare (NASDAQ:VMD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. The company had revenue of $58.00 million during the quarter. Viemed Healthcare had a return on equity of 8.72% and a net margin of 4.87%.
Insider Buying and Selling
In other news, Director Randy E. Dobbs sold 36,261 shares of Viemed Healthcare stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $9.28, for a total value of $336,502.08. Following the transaction, the director now owns 107,706 shares of the company's stock, valued at $999,511.68. The trade was a 25.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Nitin Kaushal sold 5,995 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $8.58, for a total transaction of $51,437.10. Following the sale, the director now directly owns 126,843 shares of the company's stock, valued at approximately $1,088,312.94. This represents a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,256 shares of company stock valued at $674,739 over the last quarter. Corporate insiders own 20.00% of the company's stock.
About Viemed Healthcare
(
Free Report)
Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
See Also
Before you consider Viemed Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viemed Healthcare wasn't on the list.
While Viemed Healthcare currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
